LOS ANGELES -- A yearly 15-minute infusion of a new drug substantially reduces bone fractures in post menopausal women, offering a new treatment for women who have trouble taking existing bone-strengthening drugs, researchers reported yesterday.
Although drugs such as Fosamax and Actonel are effective at preventing bone loss and reducing the major health risks associated with fractures, as many as half of women stop taking them within six months because of the complicated regimen required and the risk of side effects.
The new drug, called zoledronic acid, "requires an encounter with the medical establishment only once a year, so there is no problem with compliance and adherence," said Dr. Robert Recker, with the Creighton University School of Medicine in Nebraska.
The drug also avoids the esophageal problems that are common with the oral drugs, said Recker, who is vice president of the National Osteoporosis Foundation and was not involved in the study.
The three-year study of 7,736 postmenopausal women found a 70 percent reduction in the risk of spinal fractures and a 40 percent reduction in the risk of hip fractures. "But even more remarkable were the strong, significant, and consistent effects across all fracture types," said epidemiologist Dennis Black of the University of California at San Francisco School of Medicine, who led the study.
The results were "impressive," wrote Dr. Juliet Compston, from the University of Cambridge School of Clinical Medicine in Britain, in an editorial accompanying the report in the New England Journal of Medicine.
The drug already is sold by drug maker
The company is applying to the Food and Drug Administration to sell it under the name Reclast for treatment of osteoporosis.
About 10 million people in the United States suffer from osteoporosis, and another 34 million have low bone density and are at risk for the disorder, according to the osteoporosis foundation. One out of two women over the age of 50 will suffer a broken bone, and many of those can be serious.
The trial was sponsored by Novartis, and the researchers received grants or other support from pharmaceutical companies.